A Phase III Study Of Gemcitabine, Dexamethasone, And Cisplatin Compared To Dexamethasone, Cytarabine, And Cisplatin Plus/Minus Rituximab [(R)-GDP vs (R)-DHAP] As Salvage Chemotherapy For Patients With Relapsed Or Refractory Aggressive Histology Non-Hodgkin's Lymphoma Prior To Autologous Stem Cell Transplant And Followed By Maintenance Rituximab Versus Observation
- Compare the response rate and transplantation rate in patients with relapsed or
refractory aggressive non-Hodgkin's lymphoma when treated with salvage chemotherapy
comprising dexamethasone, cisplatin, and gemcitabine with or without rituximab vs a
standard platinum-based regimen (dexamethasone, cisplatin, and high-dose cytarabine
with or without rituximab).
- To compare the transplantation rates of the two protocol salvage regimens.
- Compare the event-free and overall survival of patients treated with these regimens.
- Compare the success rate of these regimens, in terms of getting patients to autologous
stem cell transplantation and successful mobilization after high-dose chemotherapy.
- Compare the quality of life of patients treated with these salvage regimens.
- Compare the toxic effects of these salvage regimens in these patients.
- Compare resource utilization for patients treated with these salvage regimens.
- Compare relative medical and societal costs of these salvage regimens with outcomes in
- Compare the 2-year event-free survival of patients with CD20+ B-cell lymphoma treated
with maintenance rituximab after these salvage regimens and autologous stem cell
transplantation to those patients who received no further treatment.
- Compare the 2-year survival of patients treated with or without maintenance rituximab.
- Compare the toxic effects of rituximab vs observation alone in these patients.
OUTLINE: This is a randomized, multicenter study. For salvage therapy, patients are
stratified according to participating center, International Prognostic Index score at
relapse/study entry (0 or 1 vs 2 vs ≥ 3), immunophenotype (B cell vs T cell), response to or
response duration after initial chemotherapy (no response or progressive disease vs > 1 year
vs ≤ 1 year), and prior rituximab (yes vs no). For maintenance therapy, patients are
stratified according to participating center, salvage therapy treatment randomization (with
or without rituximab, cisplatin, dexamethasone, and gemcitabine vs with or without
rituximab, cisplatin, dexamethasone, and cytarabine), response to salvage therapy (complete
response [CR] and CR unconfirmed [CRu] vs partial response [PR] vs stable disease [SD]), and
prior rituximab (yes vs no).
- Salvage therapy: Patients are randomized to 1 of 2 treatment arms.
- Arm I: Patients receive cisplatin IV over 60 minutes on day 1, dexamethasone IV or
orally on days 1-4, and gemcitabine IV over 30 minutes on days 1 and 8. Patients
with CD20+ B cell lymphoma receive rituximab IV over 1.5-6 hours on day 1.
- Arm II: Patients receive cisplatin IV over 24 hours on day 1, dexamethasone as in
arm I, and cytarabine IV over 3 hours every 12 hours for a total of 2 doses on day
2. Patients with CD20+ B cell lymphoma receive rituximab IV over 1.5-6 hours on
In both arms, treatment repeats every 21 days for at least 2 courses in the absence of
disease progression or unacceptable toxicity.
Patients are reassessed after 2 courses. Patients with progressive disease are removed from
study. Patients with a CR, CRu, or PR proceed to autologous stem cell transplantation
(ASCT). Patients with SD may proceed to ASCT or receive 1 additional course of salvage
therapy at the discretion of the investigator. Patients receiving an additional course of
salvage therapy are then reassessed after the completion of therapy. Patients with
progressive disease are removed from study. Patients with a PR proceed to ASCT. Patients
with SD may proceed to ASCT or be followed off study at the discretion of the investigator.
- ASCT: Responding patients (or those with stable disease, if that is the center's
policy)undergo mobilization, stem cell harvest, and subsequent ASCT. Patients with
CD20+ B-cell disease are randomized to maintenance therapy or observation.
- Maintenance therapy: Patients are randomized to 1 of 2 treatment arms.
- Arm I: Beginning on day 28 posttransplantation, patients receive rituximab IV once
every 2 months for 6 doses (a total of 12 months) in the absence of disease
progression or unacceptable toxicity.
- Arm II: Patients undergo observation only. Quality of life is assessed at
baseline, days 1 and 10 of course 2, day 1 of course 3 (if given), on the last day
of salvage therapy (or the first day of mobilization, if given), and at 1 month
Patients who undergo ASCT are followed at months 1, 3, 7, 13, 19, and 25 and then annually
thereafter. Patients who complete salvage therapy, but do not undergo ASCT are followed at
months 4, 8, 14, 20, and 26 and then annually thereafter. Patients who relapse or progress
are followed every 6 months until 25 months from ASCT or 26 months from completion of
salvage therapy and then annually thereafter.
PROJECTED ACCRUAL: A total of 637 patients will be accrued for this study within 3-4 years
for the first randomization, and 240 transplanted CD20+ patients will be needed for the
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Response rate of patients on treatment arm I after 2 courses of chemotherapy
Michael R. Crump, MD, FRCPC
Princess Margaret Hospital, Canada
Canada: Health Canada
|University of Pittsburgh Cancer Institute||Pittsburgh, Pennsylvania 15213|
|Hackensack University Medical Center||Hackensack, New Jersey 07601|
|Indiana University Medical Center||Indianapolis, Indiana 46202|
|Rush-Presbyterian-St. Luke's Medical Centre||Chicago, Illinois 60612|
|University of Cincinnati, Barrett Cancer Centre||Cincinnati, Ohio 45219|